CN1126473A - 化学组合物 - Google Patents

化学组合物 Download PDF

Info

Publication number
CN1126473A
CN1126473A CN94192683A CN94192683A CN1126473A CN 1126473 A CN1126473 A CN 1126473A CN 94192683 A CN94192683 A CN 94192683A CN 94192683 A CN94192683 A CN 94192683A CN 1126473 A CN1126473 A CN 1126473A
Authority
CN
China
Prior art keywords
formula
compound
group
carbazole
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94192683A
Other languages
English (en)
Chinese (zh)
Inventor
P·C·切里
J·D·科克
A·D·西尔勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1126473A publication Critical patent/CN1126473A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN94192683A 1993-05-21 1994-05-19 化学组合物 Pending CN1126473A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939310635A GB9310635D0 (en) 1993-05-21 1993-05-21 Chemical compounds
GB9310635.9 1993-05-21

Publications (1)

Publication Number Publication Date
CN1126473A true CN1126473A (zh) 1996-07-10

Family

ID=10736007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94192683A Pending CN1126473A (zh) 1993-05-21 1994-05-19 化学组合物

Country Status (19)

Country Link
EP (1) EP0699196A1 (enExample)
JP (1) JPH08510455A (enExample)
CN (1) CN1126473A (enExample)
AU (1) AU6928794A (enExample)
BG (1) BG100154A (enExample)
CA (1) CA2162921A1 (enExample)
CZ (1) CZ305195A3 (enExample)
FI (1) FI955587A7 (enExample)
GB (1) GB9310635D0 (enExample)
HU (1) HUT73790A (enExample)
IL (1) IL109703A0 (enExample)
NO (1) NO954681L (enExample)
OA (1) OA10195A (enExample)
PE (1) PE31195A1 (enExample)
PL (1) PL311702A1 (enExample)
SK (1) SK142495A3 (enExample)
TW (1) TW279866B (enExample)
WO (1) WO1994027989A1 (enExample)
ZA (1) ZA943494B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092352A1 (en) * 2007-01-26 2008-08-07 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Antitumor compounds and their preparation method

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721943A4 (en) * 1993-09-30 1996-09-04 Yamanouchi Pharma Co Ltd AZOL DERIVATIVES AND PHARMACEUTICAL PREPARATIONS
WO1996014090A1 (en) * 1994-11-07 1996-05-17 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
NZ302392A (en) * 1995-03-01 1998-08-26 Yamanouchi Pharma Co Ltd Tricyclic substituted imidazole derivatives and medicaments thereof
CN1251577A (zh) * 1997-02-21 2000-04-26 武田药品工业株式会社 稠环化合物及其生产和应用
CA2429133C (en) 2000-11-17 2009-08-18 Takeda Chemical Industries, Ltd. Novel imidazole derivatives, production method thereof and use thereof
DE60144246D1 (de) 2000-11-20 2011-04-28 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
WO2002046186A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
AU2006262283B2 (en) * 2005-06-24 2011-10-13 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (SARM)
GB0525323D0 (en) 2005-12-13 2006-01-18 Sterix Ltd Compound
US8093279B2 (en) 2005-12-13 2012-01-10 Gillian Reed, legal representative Compound
PE20121048A1 (es) 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
JP5964756B2 (ja) * 2010-02-04 2016-08-03 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
KR101594660B1 (ko) 2010-08-04 2016-02-16 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
AU2014241816B9 (en) 2013-03-14 2019-02-14 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
WO2016040896A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
WO2018080933A1 (en) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229934B2 (en) * 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092352A1 (en) * 2007-01-26 2008-08-07 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Antitumor compounds and their preparation method

Also Published As

Publication number Publication date
NO954681D0 (no) 1995-11-20
PE31195A1 (es) 1995-10-18
FI955587A0 (fi) 1995-11-20
IL109703A0 (en) 1994-08-26
WO1994027989A1 (en) 1994-12-08
NO954681L (no) 1995-11-20
CZ305195A3 (en) 1996-06-12
OA10195A (en) 1996-12-18
AU6928794A (en) 1994-12-20
HUT73790A (en) 1996-09-30
PL311702A1 (en) 1996-03-04
CA2162921A1 (en) 1994-12-08
JPH08510455A (ja) 1996-11-05
TW279866B (enExample) 1996-07-01
ZA943494B (en) 1995-01-23
FI955587A7 (fi) 1995-11-20
EP0699196A1 (en) 1996-03-06
GB9310635D0 (en) 1993-07-07
BG100154A (en) 1996-07-31
SK142495A3 (en) 1996-06-05
HU9503321D0 (en) 1996-01-29

Similar Documents

Publication Publication Date Title
CN1158274C (zh) 苯并吡喃类化合物及其使用方法
CN1131217C (zh) 苯基吡咯化合物和其制备方法及抗高血脂药
CN1323079C (zh) 血管紧张肽原酶抑制剂
CN100347164C (zh) 苯并呋喃基衍生物及其应用
JPH08510455A (ja) １７，２０―リアーゼ阻害活性を有するカルバゾール誘導体
CN1478087A (zh) 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
EP2367812B1 (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4trifluoromethoxy-1h-indol-3-yl]methanone as an inhibitor of mast cell tryptase
JP2008531668A (ja) 微結晶型（５−フルオロ−２−メチル−３−キノリン−２−イルメチル−インドール−１−イル）−酢酸
CN1051551C (zh) 新型吡咯并咔唑衍生物
EP2265582B1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
CN115485030A (zh) 咪唑并三嗪通过抑制cdk12作用于癌症
CN1882606A (zh) 雌激素受体调节剂
CN1058404A (zh) 苯并咪唑的新型衍生物、其制备及其药物用途
WO1997000257A1 (en) Fused imidazole derivatives and medicinal composition thereof
CN1429223A (zh) 新颖苯并呋喃衍生物
CN1738800A (zh) 用于治疗雄激素依赖性疾病的3型17β－羟基类固醇脱氢酶抑制剂
KR20000069128A (ko) 알파-2 아드레날린수용체 아고니스트로서 유용한 2-이미다졸리닐아미노벤즈옥사졸 화합물
CN1309642A (zh) 具有止喘、抗变态反应、抗炎、免疫调节和神经保护作用的新的1,2,5－三取代1,2－二氢吲唑－3－酮类化合物、其制备方法以及作为药物的应用
CN1137793A (zh) 用作α2肾上腺素能受体兴奋剂的6-(2-咪唑啉基氨基)喹啉化合物
CN1089264A (zh) 异苯并呋喃酮衍生物
SG178482A1 (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
CN1092074A (zh) 二氮杂䓬衍生物
EP1940840B1 (fr) Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique
CN1058778A (zh) 吲哚衍生物
CN1411457A (zh) 取代的吡咯类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication